Our Team
Mission
In pursuit of delivering patients the fastest possible visual restoration gene therapy
More than a million patients worldwide with inherited retinal disease are still waiting for an effective treatment that can end their fear of going blind.
Seeing them firsthand, a mission-driven ophthalmologist founded Restore Vision to develop a gene therapy to stop—even reverse—the disease in its tracks.
We can see a future where this too will be a treatable condition. And we want you to see it too.
Leadership
-
Yusaku Katada MD, PhD
CEO/CMO -
Hikaru Miyazaki
COO -
Yuko Fukushima CPA
CAO -
Taka Tadokoro MD, PhD
CSO, Head of R&D
Advisers
-
Hitoshi Kawamura PhD
R&D advisor -
Tsutomu Uchiyama PhD
IP Strategy Advisor -
Ken Shimokawa PhD
Strategic Advisor -
Andra Miller PhD
CMC Advisor -
Emi Mitsuya
Language Advisor -
Elizabeth K. Messersmith PhD
Consultant, Clinical Dev. and R&D Strategy -
Tetsu Yung PhD, MBA
Consultant, Project Management -
Hideki Kandori PhD
Scientific Advisor -
Mark Pennesi MD, PhD
Scientific Advisor -
Michel Michaelides MD
Scientific Advisor -
Rajendra S. Apte, MD, PhD
Scientific Advisor -
Peter K. Kaiser, MD
Scientific Advisor
About Us
| Company Name | Restore Vision Inc. |
|---|---|
| Location |
|
| Established | November 14, 2016 |
| Representative |
Yusaku Katada MD, PhD Hikaru Miyazaki |
| Business Activities | Research and development of regenerative medicine |